5FU8小时静滴联合CF、卡铂治疗晚期鼻咽癌的临床研究

目的：根据５ＦＵ，ＣＦ药代动力学特点，设计５ＦＵ连续８小时静滴，ＣＦ１００ｍｇ，在５ＦＵ静滴第０，４，８小时３次静推的ＣＦ／５ＦＵ给药方案，联合卡铂对晚期鼻咽癌患者进行临床研究，重点摸索该联合化疗方案的剂量限制性毒性及５ＦＵ的最大耐受剂量（ＭＴＤ）方法：将符合入选条件的病例分组。互助 ３－５例，５ＦＵ剂量从５００ｍｇ／（ｍ＾２·ｄ）开始，以１２５ｍｇ／（ｍ＾２·ｄ）逐渐递增，直至最大耐受剂量，ＣＦ

Clinical trial of 5FU/CF and carboplatin combination chemotherapy in patients with advanced nasopharyngeal carcinoma(NPC)

bjective: Based on the background of pharmacokinetics of 5FU and leucovorin (CF),we designed a new CF/5FU and carboplatin regimen,which consisted of 5FU by 8 hours continuous infusion for 5 days (d15),CF 100 mg iv in bolus at 0,4,8 hour throughout the duration of 5FU infusion,together with fixed dose of carbopiatin 300350 mg/m2 administered ivd on d6 to perform dosefinding clinical trail in patients with advanced NPC to establis the adequate dose of 5FU. Methods: 21 eligible patients were divided into five groups,each including 35 cases.5FU initial dose was 500 mg/(m2d) escalation of each groups by 125 mg/(m2d) until maximum tolerated dose (MTD). Results: MTD of 5FU in this combination regimen was 1000mg/(m2d)with toxicity of oral mucositis being dose limiting. Overall response rate of 762%were observed. Conclusion: The dose of 5FU at 750875 mg/(m2d) was recommended in this combination phase clinical trail.However,the high response of rate this combination regimen was needed to be confirmed in further control study.